BioCardia (BCDA) Expected to Announce Earnings on Wednesday

BioCardia (NASDAQ:BCDA) is anticipated to release its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:30 PM ET.

BioCardia (NASDAQ:BCDA) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.14. On average, analysts expect BioCardia to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioCardia Price Performance

Shares of BioCardia stock opened at $1.11 on Tuesday. BioCardia has a 12-month low of $1.00 and a 12-month high of $2.92. The stock has a market cap of $12.14 million, a P/E ratio of -0.86 and a beta of 0.56. The business’s 50 day moving average is $1.20 and its 200-day moving average is $1.27.

Institutional Investors Weigh In On BioCardia

A number of large investors have recently added to or reduced their stakes in BCDA. Cetera Investment Advisers bought a new stake in BioCardia in the 2nd quarter valued at $40,000. DRW Securities LLC bought a new stake in BioCardia in the 4th quarter valued at $72,000. Finally, Geode Capital Management LLC raised its stake in BioCardia by 70.4% in the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after acquiring an additional 27,263 shares during the period. Institutional investors own 20.57% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCardia in a research note on Monday, April 20th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $25.00.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.